Chanelle Pharma appoints Angelo Gatto to drive growth and expansion
Chanelle Pharma, Ireland’s largest manufacturer of generic pharmaceuticals for human and animal health, has appointed Angelo Gatto (pictured) as CEO. Angelo Gatto brings 25 years of international experience in pharmaceuticals, in a career spanning animal health, human health and CDMO. He has held operational, commercial and management roles at Johnson & Johnson, Pfizer, Aenova Group, and most recently, Adragos Pharma.
Chanelle Pharma employs more than 700 people in Ireland, the UK, Portugal and Jordan. Headquartered in Loughrea, County Galway, Chanelle Pharma operates four manufacturing and five R&D facilities. Its global supply chain and distribution network exports to over 80 countries.
In February 2024, Chanelle Pharma was acquired by Exponent, a leading European private equity firm. Having played a key role on Exponent’s advisory team at the time of its investment in Chanelle Pharma, Angelo Gatto has now joined the business to lead the next phase of its growth.
Chairman Carsten Hellmann said: “I am very pleased to announce the appointment of Angelo Gatto as CEO of Chanelle Pharma, following a global search. Angelo brings relevant experience in all our business areas, and has demonstrated remarkable excellence throughout his entire career. I am confident in his ability to lead Chanelle Pharma through this exciting next chapter.”
Angelo Gatto commented: “Chanelle Pharma has built an incredible brand with strong foundations and a unique positioning for ‘one-health’ which focuses on both human and animal health. I look forward to working closely with our team, leveraging strong capabilities to foster our emerging product pipeline.”
